Ahlgren GM et al., 2018-06: SPCG-12 randomised 459 men to six cycles of adjuvant docetaxel or surveillance after radical prostatectomy for high-risk disease. The 5-year risk of progression was 45% with docetaxel vs 38% with surveillance (restricted mean survival 43 vs 46 months; p=0.06), and serious adverse events were 116 vs 41.
Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy.
Abstract (CONCLUSIONS)
Ahlgren GM et al., 2018-06: SPCG-12 randomised 459 men to six cycles of adjuvant docetaxel or surveillance after radical prostatectomy for high-risk disease. The 5-year risk of progression was 45% with docetaxel vs 38% with surveillance (restricted mean survival 43 vs 46 months; p=0.06), and serious adverse events were 116 vs 41. Funder: not disclosed in the public abstract; full text is paywalled at Elsevier – the European Urology funding and disclosure statements were not accessible in this run, and no industry sponsor is named in the abstract. Maker: docetaxel (Sanofi's Taxotere) given as 75 mg/m2 every 3 weeks. Comparator: surveillance (no treatment). Note the direction of the point estimate favours surveillance; the authors call the difference nonsignificant. Study type: randomized trial.
